Hydroxylation at C-3′ of doxorubicin alters the selected phenotype of cellular drug resistance

Leonard Lothstein, Trevor W. Sweatman, Waldemar Priebe

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Hydroxylation at C-3′ of doxorubicin (DOX) yields the uncharged congener hydroxyrubicin, which circumvents P-glycoprotein-mediated drug resistance without loss of topoisomerase II inhibitory activity. Hydroxyrubicin-resistant cells exhibit a phenotype that is uniquely different from DOX resistance by expressing non-functional P-glycoprotein and hypersensitivity to anti-mitotic drugs.

Original languageEnglish (US)
Pages (from-to)1807-1812
Number of pages6
JournalBioorganic and Medicinal Chemistry Letters
Volume5
Issue number16
DOIs
StatePublished - Aug 17 1995

Fingerprint

Hydroxylation
P-Glycoprotein
Drug Resistance
Doxorubicin
Phenotype
Type II DNA Topoisomerase
Pharmaceutical Preparations
Hypersensitivity
3'-deamino-3'-hydroxydoxorubicin

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Molecular Medicine
  • Molecular Biology
  • Pharmaceutical Science
  • Drug Discovery
  • Clinical Biochemistry
  • Organic Chemistry

Cite this

Hydroxylation at C-3′ of doxorubicin alters the selected phenotype of cellular drug resistance. / Lothstein, Leonard; Sweatman, Trevor W.; Priebe, Waldemar.

In: Bioorganic and Medicinal Chemistry Letters, Vol. 5, No. 16, 17.08.1995, p. 1807-1812.

Research output: Contribution to journalArticle

@article{3a806bf700524cd396b2404d6cca6d31,
title = "Hydroxylation at C-3′ of doxorubicin alters the selected phenotype of cellular drug resistance",
abstract = "Hydroxylation at C-3′ of doxorubicin (DOX) yields the uncharged congener hydroxyrubicin, which circumvents P-glycoprotein-mediated drug resistance without loss of topoisomerase II inhibitory activity. Hydroxyrubicin-resistant cells exhibit a phenotype that is uniquely different from DOX resistance by expressing non-functional P-glycoprotein and hypersensitivity to anti-mitotic drugs.",
author = "Leonard Lothstein and Sweatman, {Trevor W.} and Waldemar Priebe",
year = "1995",
month = "8",
day = "17",
doi = "10.1016/0960-894X(95)00300-I",
language = "English (US)",
volume = "5",
pages = "1807--1812",
journal = "Bioorganic and Medicinal Chemistry Letters",
issn = "0960-894X",
publisher = "Elsevier Limited",
number = "16",

}

TY - JOUR

T1 - Hydroxylation at C-3′ of doxorubicin alters the selected phenotype of cellular drug resistance

AU - Lothstein, Leonard

AU - Sweatman, Trevor W.

AU - Priebe, Waldemar

PY - 1995/8/17

Y1 - 1995/8/17

N2 - Hydroxylation at C-3′ of doxorubicin (DOX) yields the uncharged congener hydroxyrubicin, which circumvents P-glycoprotein-mediated drug resistance without loss of topoisomerase II inhibitory activity. Hydroxyrubicin-resistant cells exhibit a phenotype that is uniquely different from DOX resistance by expressing non-functional P-glycoprotein and hypersensitivity to anti-mitotic drugs.

AB - Hydroxylation at C-3′ of doxorubicin (DOX) yields the uncharged congener hydroxyrubicin, which circumvents P-glycoprotein-mediated drug resistance without loss of topoisomerase II inhibitory activity. Hydroxyrubicin-resistant cells exhibit a phenotype that is uniquely different from DOX resistance by expressing non-functional P-glycoprotein and hypersensitivity to anti-mitotic drugs.

UR - http://www.scopus.com/inward/record.url?scp=0029133098&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029133098&partnerID=8YFLogxK

U2 - 10.1016/0960-894X(95)00300-I

DO - 10.1016/0960-894X(95)00300-I

M3 - Article

VL - 5

SP - 1807

EP - 1812

JO - Bioorganic and Medicinal Chemistry Letters

JF - Bioorganic and Medicinal Chemistry Letters

SN - 0960-894X

IS - 16

ER -